Differential levels of dendritic cell maturation on different biomaterials used in combination products
Differential levels of dendritic cell maturation on different biomaterials used in combination products
复制标题
DOI：
10.1002/jbm.a.30429
复制
发表时间：
2005-09-15
影响因子：
4.9
通讯作者：
Paranjpe, A
中科院分区：
文献类型：
--
作者：
Babensee, JE;Paranjpe, A
未成熟树突状细胞(IDCs)来自人外周血单核细胞，用组合产品(如组织工程构建物或疫苗)中常用的生物材料薄膜处理，以评估结果树突状细胞(DC)成熟，与脂多糖(LPS)治疗的阳性对照DC成熟或未处理IDCs的阴性对照进行比较。生物材料包括：海藻酸盐、琼脂糖凝胶、壳聚糖、透明质酸、75：25聚乳酸-羟基乙酸(PLGA)。DC培养对这些薄膜的影响被用来识别支持DC成熟的生物材料和不支持DC成熟的生物材料。与对照组相比，经壳聚糖或PLGA(琼脂糖凝胶程度较低)膜处理的树突状细胞CD86、CD40和HLA-DQ的表达水平升高，与脂多糖成熟的树突状细胞相似，而经海藻酸盐或透明质酸膜处理的树突状细胞这些分子的表达水平降低。总而言之，就诱导DC成熟的程度而言，观察到培养IDCs的生物材料的不同效果。生物材料对DC成熟的影响及其相关的佐剂效应是一种新的生物相容性选择和设计标准，可用于免疫后果为潜在并发症或结果的组合产品。(C)2005年威利期刊公司。
Immature dendritic cells (iDCs) were derived from human peripheral blood monocytes, and treated with films of biomaterials commonly used in combination products (e.g., tissue engineered constructs or vaccines) to assess the resultant dendritic cell (DC) maturation compared to positive control of lipopolysaccharide (LPS) treatment for DC maturation or negative control of untreated iDCs. The following biomaterials were tested: alginate, agarose, chitosan, hyaluronic acid, 75:25 poly(lactic-co-glycolic acid) (PLGA). The effect of DC culture on these films was undertaken to identify biomaterials which support DC maturation and those biomaterials that did not. Dendritic cells treated with chitosan or PLGA (agarose to a lesser extent) films increased expression levels of CD86, CD40, and HLA-DQ, compared to control iDCs, similar to LPS-matured DCs whereas DCs treated with alginate or hyaluronic acid films decreased their expression levels of these same molecules. In summary, a differential effect of the biomaterial on which iDCs were cultured was observed as far as the extent of induced DC maturation. The effect of biomaterials on DC maturation, and the associated adjuvant effect, is a novel biocompatibility selection and design criteria for biomaterials to be used in combination products in which immune consequences are potential complications or outcomes. (c) 2005 Wiley Periodicals, Inc.